BioInvent And ThromboGenics Announce A Strategic Alliance With Roche For TB-403, A Novel Anti-Cancer Antibody

June 19th, 2008 | Category: Cancer

BioInvent worldly AB (STO:BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF),

one of the growth factors responsible for the development of new blood vessels. Under the terms of the agreement effective from June 17, 2008 (or whether a U.S.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • ThromboGenics And BioInvent Receive Approval To start Clinical Trials Of TB 403 For The Treatment Of Cancer
  • ThromboGenics And BioInvent Report Positive Phase I Results For Anti-PlGF Cancer Therapeutic TB-403
  • Bioinvent And Thrombogenics Report Positive Phase I Results For Anti-Plgf Cancer Therapeutic TB-403
  • Is Earlier Detection Of Cancers Such As Glioma Possible?
  • Affitech-Identified Fully Human Anti-VEGF Antibody Candidate Is As Effective As Avastin(R) In Preclinical Cancer Models

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.